%0 Journal Article
%A Fernandez-Mateos, J.
%A Seijas-Tamayo, R.
%A Mesia, R.
%A Taberna, M.
%A Pastor Borgonon, M.
%A Perez-Ruiz, E.
%A Klain, J. C. Adansa
%A Vazquez Fernandez, S.
%A del Barco Morillo, E.
%A Lozano, A.
%A Gonzalez Sarmiento, R.
%A Cruz-Hernandez, J. J.
%A Spanish Head Neck Canc Cooperative
%T Epidermal growth factor receptor (EGFR) pathway polymorphisms as predictive markers of cetuximab toxicity in locally advanced head and neck squamous cell carcinoma (HNSCC) in a Spanish population
%D 2016
%@ 1368-8375
%U https://hdl.handle.net/10668/26658
%X Objectives: To examine the relationship between polymorphisms of the epidermal growth factor receptor (EGFR) pathway and toxicity in head and neck squamous cell carcinoma (HNSCC) patients treated with cetuximab.Material and methods: Multicenter, retrospective, observational pilot study which included 110 patients with histologically-confirmed human papillomavirus (HPV) negative HNSCC in locally advanced stages (III-IVA-B) and who were treated with chemotherapy and radiotherapy plus cetuximab between 2003 and 2013. Genetic analyses for single nucleotide polymorphisms (SNP) in genes EGFR, CCDN1, FCGR2A, FCGR3A and KRAS-LCS6 were performed though available allelic discrimination assay and/or polymerase chain reaction-restriction fragment length polymorphism methods.Results: Acneiform rash was observed in 55.5% of patients, dry skin in 45.5% and pruritus in 20.9%. A significant association with dry skin and global cetuximab-related toxicity was observed for the KRAS-LCS6 (rs61764370) variant (p
%K Head and neck squamous cell carcinoma (HNSCC)
%K Epidermal growth factor receptor (EGFR)
%K Polymorphism
%K SNP
%K EGFR
%K CCDN1
%K FCGR2A
%K FCGR3A
%K KRAS-LCS6
%K Cetuximab
%K Toxicity
%K Platinum-based chemotherapy
%K Phase-ii
%K Plus cetuximab
%K Skin toxicity
%K Single-agent
%K Lung-cancer
%K Open-label
%K Risk
%K Epidemiology
%K Combination
%~